Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Common Equity (2022 - 2025)

Envoy Medical's Common Equity history spans 4 years, with the latest figure at -$12.2 million for Q4 2025.

  • Quarterly results put Common Equity at -$12.2 million for Q4 2025, up 35.47% from a year ago — trailing twelve months through Dec 2025 was -$12.2 million (up 35.47% YoY), and the annual figure for FY2025 was -$12.2 million, up 35.47%.
  • Common Equity for Q4 2025 was -$12.2 million at Envoy Medical, down from -$7.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $4.8 million in Q3 2023 to a low of -$47.5 million in Q1 2023.
  • The 4-year median for Common Equity is -$21.5 million (2024), against an average of -$20.9 million.
  • The sharpest move saw Common Equity skyrocketed 118.74% in 2023, then plummeted 960.92% in 2024.
  • Year by year, Common Equity stood at -$36.2 million in 2022, then skyrocketed by 95.09% to -$1.8 million in 2023, then plummeted by 960.92% to -$18.8 million in 2024, then surged by 35.47% to -$12.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$12.2 million, -$7.7 million, and -$29.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.